NCI Outstanding Investigator Award (with up to $600,000 a year) goes to 17 scientists

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

A University of Oklahoma physician-researcher recently received $2.9 million in funding from NCI to study whether RedHill Biopharma’s drug opaganib, given after CAR T-cell therapy, can help the immune cells fight cancer more effectively.

October 23, 2026

Vol.52 No.39

Funding Opportunities

International Myeloma Society opens applications for over $3M in 2027 research funding

The International Myeloma Society, in partnership with the Paula and Rodger Riney Foundation, is accepting applications for more than $3 million in research funding through its 2027 Translational Research and Career Development awards. The awards support research to improve the prevention, early detection, diagnosis, and treatment of multiple myeloma and related plasma cell disorders, while developing the next generation of researchers in the field.

October 23, 2026

Vol.52 No.39

Cancer Policy

Letai announces: NCI met FY26 goal of full funding payout

In a post on NCI’s LinkedIn, NCI Director Anthony Letai confirmed that the institute has fully awarded and paid out all of its grant funding for the Fiscal Year 2026.

October 16, 2026

Vol.52 No.38

By Claire Marie Porter

In Brief

William Freed-Pastor wins Steven A. Rosenberg Scholars Award

William Freed-Pastor has been named the 2026 Steven A. Rosenberg Scholars Award recipient, according to the Society for Immunotherapy of Cancer Forward Fund.

October 16, 2026

Vol.52 No.38

In Brief

Keith Argenbright receives CPRIT’s Texans Conquer Cancer Award in Population Health

Keith Argenbright, director of the Moncrief Cancer Institute at UT Southwestern Medical Center, received the 2026 Texans Conquer Cancer Award in Population Health from the Cancer Prevention and Research Institute of Texas on Oct. 5.

October 16, 2026

Vol.52 No.38

Podcast

As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”

As the oncology community waits with bated breath for a possible FDA approval of GRAIL’s Galleri test, NCI Director Anthony Letai has a lot to say about multi-cancer detection tests—particularly Galleri.

October 14, 2026

NCI Outstanding Investigator Award (with up to $600,000 a year) goes to 17 scientists

YOU MAY BE INTERESTED IN

OU receives $2.9M NCI grant to study opaganib to enhance CAR T-cell therapy in multiple myeloma

International Myeloma Society opens applications for over $3M in 2027 research funding

Letai announces: NCI met FY26 goal of full funding payout

William Freed-Pastor wins Steven A. Rosenberg Scholars Award

Keith Argenbright receives CPRIT’s Texans Conquer Cancer Award in Population Health

As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”

Renew today!

Subscriber content

Never miss an issue!

Login